Literature DB >> 21586677

Inhibitory effect of prostaglandin I2 on bone marrow kinetics of eosinophils in the guinea pig.

Eva M Sturm1, Rufina Schuligoi, Viktoria Konya, Gunter J Sturm, Akos Heinemann.   

Abstract

Enhanced eosinophil trafficking from bone marrow to the tissue is a hallmark of allergic diseases. We have shown previously that PGI(2) markedly attenuates the locomotion of human eosinophils in vitro. Here, we set out to determine the effect of PGI(2) on the trafficking of bone marrow eosinophils in the guinea pig. Shape change of bone marrow eosinophils was determined by flow cytometry, and chemotaxis assays were performed using a transwell migration system. Eosinophil release from bone marrow of guinea pigs was investigated in the isolated, perfused hind-limb preparation. We found that PGI(2) prevented the mobilization of eosinophils from bone marrow and attenuated the shape change and chemotactic responses of bone marrow eosinophils. These effects were mimicked by iloprost and were prevented by the IP antagonist CAY10441 and the adenylyl cyclase inhibitor SQ22536. Immunohistochemical staining of bone marrow confirmed the expression of IPs by bone marrow eosinophils. The rate-limiting enzyme of PGI(2) formation, PGIS, was found in large mononuclear cells. These data show that IP activation negatively modulates the mobilization and locomotion of bone marrow eosinophils and might therefore also protect against exaggerated recruitment of eosinophils to inflammatory sites.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21586677     DOI: 10.1189/jlb.0211087

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  8 in total

1.  Prostaglandin I2 Signaling and Inhibition of Group 2 Innate Lymphoid Cell Responses.

Authors:  Weisong Zhou; Shinji Toki; Jian Zhang; Kasia Goleniewksa; Dawn C Newcomb; Jacqueline Y Cephus; Daniel E Dulek; Melissa H Bloodworth; Matthew T Stier; Vasiliy Polosuhkin; Rama D Gangula; Simon A Mallal; David H Broide; R Stokes Peebles
Journal:  Am J Respir Crit Care Med       Date:  2016-01-01       Impact factor: 21.405

Review 2.  Prostaglandin regulation of type 2 inflammation: From basic biology to therapeutic interventions.

Authors:  Oyebola O Oyesola; Elia D Tait Wojno
Journal:  Eur J Immunol       Date:  2021-09-07       Impact factor: 6.688

3.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

Review 4.  Prostaglandins in asthma and allergic diseases.

Authors:  R Stokes Peebles
Journal:  Pharmacol Ther       Date:  2018-08-03       Impact factor: 12.310

Review 5.  Emerging Role of Phospholipase-Derived Cleavage Products in Regulating Eosinophil Activity: Focus on Lysophospholipids, Polyunsaturated Fatty Acids and Eicosanoids.

Authors:  Eva Knuplez; Eva Maria Sturm; Gunther Marsche
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

6.  Immunoglobulin genomics in the guinea pig (Cavia porcellus).

Authors:  Yongchen Guo; Yonghua Bao; Qingwen Meng; Xiaoxiang Hu; Qingyong Meng; Liming Ren; Ning Li; Yaofeng Zhao
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

Review 7.  Prostaglandins and Their Receptors in Eosinophil Function and As Therapeutic Targets.

Authors:  Miriam Peinhaupt; Eva M Sturm; Akos Heinemann
Journal:  Front Med (Lausanne)       Date:  2017-07-19

Review 8.  The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy.

Authors:  Kijeong Lee; Sang Hag Lee; Tae Hoon Kim
Journal:  Int J Mol Sci       Date:  2020-03-08       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.